Skip to main content

Advertisement

SpringerLink
Log in

Cytosine arabinoside in the treatment of acute myeloid leukemia: The role and place of high-dose regimens

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Summary

Cytosine arabinoside (AraC) is one of the most active drugs in the treatment of acute leukemias and is widely applied at all phases of therapy. In spite of extensive clinical and experimental investigations, its intracellular metabolism and especially its mechanism of action are still not fully elucidated. Controversy also continues about the most appropriate way and dose of administration; which differs by more than 100 fold in clinical studies ranging from low-dose, over standard and intermediate dose regimens, to high-dose protocols.

The present review is focused on the role and place of high-dose AraC treatment in acute myeloid leukemia (AML). Based on available clinical and experimental data, the following conclusions can be drawn: Not considering possible but not yet demonstrated beneficial long-term effects, the incorporation of high-dose AraC intoinduction therapy has not resulted in an improvement of overall remission rate, with the possible exception of patients with slow initial cytoreduction after a first course of conventional treatment. Promising results, however, emerge from high-dose AraC-basedconsolidation protocols, which need confirmation in prospectively randomized comparative trials. Inrelapsed and refractory AML, higher than conventional doses undoubtedly enhance the efficacy of AraC salvage therapy. The question of whether the antileukemic activity of intermediate-dose regimens with 500–1,000 mg/m2 AraC is equivalent to that of high-dose protocols applying 2,000–3,000 mg/m2 AraC, however, remains open but may soon be answered by ongoing controlled clinical and pharmacologic investigations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Abe I, Sato S, Honi K, Suzuki M, Sato H (1982) Role of dephosphorylation in accumulation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate in human lymphoblastic cell lines with reference to their drug sensitivity. Cancer Res 42: 2846–2851

    PubMed  Google Scholar 

  2. Andreeff M, Tafuri A, Hegewisch-Becker S (1990) Colony-stimulating factors (rh G-CSF, rh GM-CSF, rh IL 3, and BCGF) recruit myeloblastic and lymphoblastic leukemic cells and enhance the cytotoxic effects of cytosine-arabinoside. In: Büchner T, Schellong G, Hiddemann W, Ritter J (eds) Acute leukemias — prognostic factors and treatment strategies. II. Springer, Berlin Heidelberg New York, pp 747–762

    Google Scholar 

  3. Baguley BC, Falkenhaug EM (1971) Plasma half-life of cytosine arabinoside (NSC-63878) in patients treated for acute myeloblastic leukemia. Cancer Chemother Rep 55: 291–298

    PubMed  Google Scholar 

  4. Barlogie B, Plunkett W, Raber M, Latreille J, Keating M, McCredie K (1981) In vivo cellular kinetic and pharmacological studies of 1-β-D-arabinofuranosylcytosine and 3-deazauridine chemotherapy for relapsing acute leukemia. Cancer Res 41: 1227–1235

    PubMed  Google Scholar 

  5. Bhalla K, Nayak R, Grant S (1984) Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-β-D-arabinofuranosylcytosine. Cancer Res 44: 5020–5037

    Google Scholar 

  6. Bhalla K, McLaughlin W, Cole J, Arlin Z, Baker M, Graham G, Grant S (1987) Deoxycytidine preferentially protects normal versus leukemia myeloid progenitor cells from cytosine arabinosidemediated cytotoxicity. Blood 70: 568–571

    PubMed  Google Scholar 

  7. Bhalla K, Birkhofer M, Arlin Z, Grant S, Lutzky J, Graham G (1988) Effect of recombinant GM-CSF on the metabolism of cytosine arabinoside in normal and leukemic human bone marrow cells. Leukemia 2: 810–813

    PubMed  Google Scholar 

  8. Blumenreich MS, Chou TC, Andreeff M, Vale K, Clarkson BD, Young CW (1984) Thymidine as a kinetic and biochemical modulator of 1-β-D-arabinofuranosylcytosine in human acute nonlymphocytic leukemia. Cancer Res 44: 825–830

    PubMed  Google Scholar 

  9. Bodey GP, Coltman CA, Hewlett JS, Freireich EJ (1976) Progress in the treatment of adults with acute leukemia. Arch Intern Med 136: 1383–1388

    PubMed  Google Scholar 

  10. Bolwell BJ, Cassileth PA, Gale RP (1987) Low-dose cytosine arabinoside in myelodysplasia and acute myelogenous leukemia: a review. Leukemia 1: 575–579

    PubMed  Google Scholar 

  11. Bolwell BJ, Cassileth PA, Gale RP (1988) High-dose cytarabine: a review. Leukemia 2: 253–260

    PubMed  Google Scholar 

  12. Breithaupt H, Pralle H, Eckhardt T, von Hattingberg M, Schick J, Löffler H (1982) Clinical results and pharmacokinetics of high-dose cytosine arabinoside (HD ARA-C). Cancer 50: 1248–1257

    PubMed  Google Scholar 

  13. Büchner T, Hiddemann W, Wendt F, Maschmeyer G, Kuse R, Löffler H (1987) Early intensification by double induction (DI) in adult AML: a multicenter study of the AML Cooperative Group. Blood 70 [Suppl 1]: 752a

    Google Scholar 

  14. Büchner T, Hiddemann W, Blasius S et al. (1980) Adult AML: the role of chemotherapy intensity and duration. Two studies of the AML Cooperative Group. In: Büchner T, Schellong G, Hiddemann W, Ritter J (eds) Acute leukemias — prognostic factors and treatment strategies. II. Springer, Berlin Heidelberg New York, pp 261–266

    Google Scholar 

  15. Büchner T, Hiddemann W (1990) Treatment strategies in acute myeloid leukemia (AML). A. First-line chemotherapy. Blut 60: 61–67

    PubMed  Google Scholar 

  16. Butturini A, Gale RP (1989) Chemotherapy versus transplantation in acute leukemia. Br J Haematol 72: 1–8

    PubMed  Google Scholar 

  17. Cannistra SA, Groshek P, Griffin JD (1989) Granulocytemacrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia. Leukemia 3: 328–333

    PubMed  Google Scholar 

  18. Cantin G, Brennan JK (1984) High-dose cytosine arabinoside for acute nonlymphocytic leukemia. Am J Hematol 16: 59–66

    PubMed  Google Scholar 

  19. Capizzi RL, Yang JL, Cheng EC, Bjornsson T, Sahasrabudhe D, Tan RS, Cheng YC (1983) Alteration of the pharmacokinetics of high dose-AraC by its metabolite, high Ara-U, in patients with acute leukemia. J Clin Oncol 1: 763–771

    PubMed  Google Scholar 

  20. Capizzi RL, Powell BL, Cooper MR, Stuart JJ, Muss HB, Richards F II, Jackson DV, White D, Spurr CL, Zekan PF, Cruz JM, Craig JB (1985) Sequential high-dose AraC and asparaginase in the therapy of previously treated and untreated patients with acute leukemia. Semin Oncol 12 [Suppl 3]: 105–113

    Google Scholar 

  21. Capizzi RL, Yang J, Rathmell JP, White JC, Cheng E, Cheng Y, Kute T (1985) Dose-related pharmacological effects of highdose AraC and its self-potentiation. Semin Oncol 12 [Suppl 3]: 65–74

    Google Scholar 

  22. Cassileth PA, Harrington DP, Hines JD, Oken MM, Mazza JJ, McGlave P, Bennett JM, Lynch E, O'Connell MJ (1990) Comparison of postremission therapies in adult acute myeloid leukemia: preliminary analysis of an ECOG study. In: Büchner T, Schellong G, Hiddemann W, Ritter J (eds) Acute leukemias — prognostic factors and treatment strategies. II. Springer, Berlin Heidelberg New York, pp 267–270

    Google Scholar 

  23. Chabner BA (1982) Cytosine arabinoside. In: Chabner BA (ed) Pharmacologic principles of cancer treatment. Saunders, Philadelphia, pp 387–401

    Google Scholar 

  24. Champlin R, Gale RP (1987) Acute myelogenous leukemia: recent advances in therapy. Blood 69: 1551–1562

    PubMed  Google Scholar 

  25. Champlin R, Ho W, Winston D, Decker R, Greenberg P, Burnison M, Holly FE, Gale P (1987) Treatment of adults with acute myelogenous leukemia: prospective evaluation of high-dose cytarabine in consolidation chemotherapy and with bone marrow transplantation. Semin Oncol 14 [Suppl 1]: 1–6

    Google Scholar 

  26. Chan TCK (1989) Augmentation of 1-β-D-arabinofuranosyl-cytosine cytotoxicity in human tumor cells by inhibiting drug efflux. Cancer Res 49: 2656–2660

    PubMed  Google Scholar 

  27. Cheson BD, Jasperse DM, Simon R, Friedman MA (1986) A critical appraisal of low-dose cytosine arabinoside in patients with acute nonlymphocytic leukemia and myelodysplastic syndromes. J Clin Oncol 4: 1857–1864

    PubMed  Google Scholar 

  28. Chu MY, Fischer GA (1965) Comparative studies on leukemic cells sensitive and resistant to cytosine arabinoside. Biochem Pharmacol 14: 333–341

    PubMed  Google Scholar 

  29. Cline MJ, Golde DW, Billing RJ, Groopman JE, Zighelboim J, Gale RP (1979) Acute leukemia: biology and treatment. Ann Intern Med 91: 758–773

    PubMed  Google Scholar 

  30. Colly LP, Peters WG, Arentsen-Honders MW, Starrenburg CWJ, Willemze R (1987) Deoxycytidine kinase and deoxycytidine deaminase values correspond closely to clinical response to cytosine arabinoside remission induction therapy in patients with acute myelogenous leukemia. Semin Oncol 14 [Suppl 1]: 257–261

    PubMed  Google Scholar 

  31. Creasey WA (1975) Arabinosylcytosine. In: Sartorelli A, John DG (eds) Handbuch der Experimentellen Pharmakologie. Antineoplastic and immunsuppressive agents. 2. Springer, Berlin Heidelberg New York, pp 232–256

    Google Scholar 

  32. Curtis JE, Messner HA, Minden MD, Minkin MD, Minkin S, McCulloch EA (1987) High-dose cytosine arabinoside in the treatment of acute myelogenous leukemia: contribution to outcome of clinical and laboratory attributes. J Clin Oncol 5: 532–543

    PubMed  Google Scholar 

  33. Daly PF, Zugmaier G, Sandler D, Carpen M, Myers CE, Cohen JS (1990) Regulation of the cytidine phospholipid pathways in human cancer cells and effects of 1-β-D-arabinofuranosylcytosine: a noninvasive31P nuclear magnetic resonance study. Cancer Res 50: 552–557

    PubMed  Google Scholar 

  34. Donehower RC, Karp JE, Burke PJ (1986) Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion. Cancer Treat Rep 70: 1059–1065

    PubMed  Google Scholar 

  35. Early AP, Preisler HD, Higby DJ, Brecher M, Browman G, McBride JA (1982) High-dose cytosine arabinoside. Clinical response to therapy in acute leukemia. Med Pediatr Oncol [Suppl 1]: 239–250

    Google Scholar 

  36. Ellison RR, Holland JF, Weil M, Jacquillat C, Boiron M, Bernard J, Sawitsky A, Rosner F, Gussoff B, Silver RT, Karanas A, Cuttner J, Spurr CL, Hayes DM, Blom J, Leone LA, Haurani F, Kyle R, Hutchinson JL, Forcier RJ, Moon JH (1968) Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood 32: 507–523

    PubMed  Google Scholar 

  37. Estey E, Keating MJ, Plunkett W, McCredie KB, Freireich E (1987) Continuous-infusion high-dose cytosine arabinoside without anthracyclines as induction and intensification therapy in adults under age 50 with newly diagnosed acute myelogenous leukemia. Semin Oncol 14 [Suppl 1]: 58–63

    PubMed  Google Scholar 

  38. Estey E, Plunkett W, Dixon D, Keating M, McCredie K, Freireich EJ (1987) Variables predicting response to high-dose cytosine arabinoside therapy in patients with refractory acute leukemia. Leukemia 8: 580–583

    Google Scholar 

  39. Evans JS, Musser EA, Mengel GD, Forsblad KR, Hunter JH (1961) Antitumor activity of 1-β-D-arabinofuranosylcytosine hydrochloride (26335). Proc Soc Exp Biol Med 106: 350–353

    PubMed  Google Scholar 

  40. Fram R, Major P, Egan E, Beardsley P, Rosenthal D, Kufe D (1983) A phase I–II study of combination therapy with thymidine and cytosine-arabinoside. Cancer Chemother Pharmacol 11: 43–47

    PubMed  Google Scholar 

  41. Frei E III, Bickers JN, Hewlett JS, Lane M, Leary W, Talley RW (1969) Dose schedule and antitumor studies of arabinosyl cytosine. Cancer Res 29: 1325–1332

    PubMed  Google Scholar 

  42. Forman SJ, Nademanee AP, O'Donnell MR, Fahey JL, Snyder DS, Farbstein MJ, Lazar GS, DuBois NJ, Blume KG (1985) High-dose cytosine arabinoside and daunorubicin as primary therapy for adults with acute nonlymphocytic leukemia: a pilot study. Semin Oncol 12 [Suppl 3]: 114–116

    PubMed  Google Scholar 

  43. Furth JJ, Cohen S (1969) Inhibition of mammalian DNA polymerase by the 5′-triphosphate of 1-β-D-arabinofuranosyladenine and the 5′-triphosphate of 9-β-arabinofuranosyladenine. Cancer Res 28: 2061–2067

    Google Scholar 

  44. Gale RP (1979) Advances in the treatment of acute myelogenous leukemia. N Engl J Med 300: 1189–1199

    PubMed  Google Scholar 

  45. Graham FL, Whitemore GF (1970) Studies in mouse L cells on the incorporation of 1-β-D-arabinofuranosylcytosine into DNA and inhibition of DNA polymerase by 1-β-D-arabinofuranosylcytosine 5′triphosphate. Cancer Res 30: 2636–2644

    PubMed  Google Scholar 

  46. Grant S, Bhalla K, Arlin Z, Howe CWS (1990) The effect of a prolonged in vitro exposure to 1-β-D-arabinofuranosylcytosine and deoxycytidine on the survival of normal (CFU-GM) and leukemic (L-CFU) human myeloid progenitor cells in suspension culture. Exp Hematol 18: 41–48

    PubMed  Google Scholar 

  47. Hagenbeek A, Martens ACM, Colly LP (1987) In vivo development of cytosine arabinoside resistance in the BN acute myelocytic leukemia. Semin Oncol 14 [Suppl 1]: 202–206

    PubMed  Google Scholar 

  48. Harousseau JL, Milpied N, Briere J, Desableus B, LePrise PY, Ifran N, Gandhour C, Casassus P (1990) Double intensive consolidation chemotherapy (ICC) for acute myeloid leukemia. In: Büchner T, Schellong G, Hiddemann W, Ritter J (eds) Acute leukemias — prognostic factors and treatment strategies. II. Springer, Berlin Heidelberg New York, pp 299–303

    Google Scholar 

  49. Hawtrey AO, Scott-Burden T, Robertson G (1974) Inhibition of glycoprotein and glycolipid synthesis in hamster embryo cells by cytosine arabinoside and hydroxyurea. Nature 252: 58–60

    PubMed  Google Scholar 

  50. Heinemann V, Estey E, Keating MJ, Plunkett W (1989) Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia. J Clin Oncol 7: 622–628

    PubMed  Google Scholar 

  51. Herzig RH, Wolff SN, Lazarus HM, Phillips GL, Karanes C, Herzig GP (1983) High-dose cytosine arabinoside therapy for refractory leukemia. Blood 62: 361–369

    PubMed  Google Scholar 

  52. Herzig RH, Hines JD, Herzig GP, Wolff SN, Cassileth PA, Lazarus HM, Adelstein DJ, Brown RA, Coccia PF, Strandjord S, Mazza JJ, Fay J, Phillips GL (1987) Cerebellar toxicity with high-dose cytosine arabinoside. J Clin Oncol 5: 927–932

    PubMed  Google Scholar 

  53. Hiddemann W, Maschmeyer G, Pfreundschuh M, Ludwig WD, Büchner T (1988) Treatment of refractory acute myeloid (AML) and lymphoblastic leukemia (ALL) with high-dose cytosine arabinoside (HD-AraC) and mitoxantrone: indication of increased efficacy by sequential administration. Proc Am Soc Clin Oncol 7: 189

    Google Scholar 

  54. Hiddemann W, Kiehl M, Schleyer E, Wörmann B, Zühlsdorf M, Büchner T (1989) Stimulatory effect of GM-CSF and IL 3 on the metabolism and cytotoxic activity of cytosine-arabinoside (ARA-C) in leukemic blasts from patients with acute myeloid leukemia (AML). Blood 74 [Suppl 1]: 230a

    Google Scholar 

  55. Hiddemann W, Martin WD, Sauerland CM, Heinecke A, Büchner T (1990) Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia — a proposal based on the results of retreatment by thioguanine, cytosine arabinoside and daunorubicin (TAD 9) in 150 patients with relapse after standardized first-line therapy. Leukemia 4: 184–188

    PubMed  Google Scholar 

  56. Hiddemann W, Büchner T (1990) Treatment strategies in acute myeloid leukemia (AML). B. Second line treatment. Blut 60: 163–171

    PubMed  Google Scholar 

  57. Hiddemann W, Schleyer E, Uhrmeister C, Aul C, Maschmeyer G, Heinecke A, Büchner T (1990) High-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia — preliminary clinical and pharmacological data of a randomized comparison. Cancer Treat Rev (in press)

  58. Hindenburg AA, Taub RN, Grant S, Chang G, Baker MA (1985) Effects of pyrimidine antagonists on sialic acid regeneration in HL-60 cells. Cancer Res 45: 3048–3052

    PubMed  Google Scholar 

  59. Hines HD, Mazzo JJ, Oken MM, Bennett JM, Adelstein DJ, Keller A, O'Connell MJ (1985) High-dose cytosine arabinoside and m-AMSA induction and consolidation in patients with previously untreated de novo acute nonlymphocytic leukemia: phase-I pilot study for the Eastern Cooperative Oncology Group. Semin Oncol 12 [Suppl 3]: 117–119

    PubMed  Google Scholar 

  60. Ho DHW, Frei E III (1971) Clinical pharmacology of 1-β-D-arabinofuranosylcytosine. Clin Pharmacol Ther 12: 944–954

    PubMed  Google Scholar 

  61. Ho DHW (1973) Distribution of kinase and deaminase of 1-β-D-arabinofuranosylcytosine in tissue of man and mouse. Cancer Res 33: 2816–2820

    PubMed  Google Scholar 

  62. Jehn U, Zittoun R, Suciu S, Fiere D, Haanen C, Peetermans M, Löwenberg B, Willemze R, Solbu G, Stryckmans P, and the EORTC Leukemia Cooperative Group (1990) In: Büchner T, Schellong G, Hiddemann W, Ritter J (eds) Acute leukemias — prognostic factors and treatment strategies. II. Springer, Berlin Heidelberg New York, pp 277–284

    Google Scholar 

  63. Kantarjian HM, Estey EH, Plunkett W, Keating MJ, Walters RS, Iacoboni S, McCredie KB, Freireich EJ (1986) Phase I–II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia. Am J Med 81: 387–394

    PubMed  Google Scholar 

  64. Karp JE, Donehower RC, Enterline JP, Dole GB, Fox MG, Burke PJ (1989) In vivo cell growth and pharmacologic determinants of clinical response in acute myelogenous leukemia. Blood 73: 24–30

    PubMed  Google Scholar 

  65. Kees UR, Ford J, Dawson VM, Piall E, Aherne GW (1989) Development of resistance to 1-β-D-arabinofuranosylcytosine after high-dose treatment in childhood lymphoblastic leukemia: analysis of resistance mechanism in established cell lines. Cancer Res 49: 3015–3019

    PubMed  Google Scholar 

  66. Kessel D, Hall TC, Wodinsky I (1967) Transport and phosphorylation as factors in the antitumor action of cytosine arabinoside. Science 156: 1240–1241

    PubMed  Google Scholar 

  67. Kline I, Venditti J, Tyrer DD, Mantel N, Goldin A (1966) Chemotherapy of leukemia L 1210 in mice with 1-β-D-arabino-furanosyl-cytosine hydrochloride. I. Influence of treatment schedules. Cancer Res 26: 853–859

    PubMed  Google Scholar 

  68. Kreis W, Chan K, Budman J, Schulman P, Allen S, Weiselberg L, Henderson V, Freeman J, Deere M, Vincinguerra V (1986) Effects of tetrahydrouridine (THU) on ara-C pharmacokinetics and toxicity when both drugs are given to patients by continuous infusion over 3 hours. Proc Am Assoc Cancer Res 27: 165

    Google Scholar 

  69. Kufe DW, Spriggs DR, Egan EM, Munroe D (1984) Relationships among ara-C pools, formation of (ara-C) DNA, and cytotoxicity of human leukemic cells. Blood 64: 54–58

    PubMed  Google Scholar 

  70. Kufe DW, Spriggs DR, Griffin JD (1987) Pharmacologic studies of low-dose and high-dose continuous infusion cytosine arabinoside. Semin Oncol 1 [Suppl 1]: 149–158

    Google Scholar 

  71. Kurrle E, Ehninger G, Fackler-Schwalbe E, Freund M, Heill G, Hoelzer D, Link H, Löffler B, Lösch A, Mitrou PS, Ohl S, Queißer W, Schlimok G, Wandt H (1990) Consolidation therapy with high-dose cytosine arabinoside: experiences of a prospective study in acute myeloid leukemia. In: Büchner T, Schellong G, Hiddemann W, Ritter J (eds) Acute leukemias — prognostic factors and treatment strategies. II. Springer, Berlin Heidelberg New York, pp 254–260

    Google Scholar 

  72. Lanzon GJ, Paran JH, Paterson ARP (1978) Formation of 1-β-D-arabinofuranosylcytosine diphosphate choline in cultured human leukemic RPMI-6410 cells. Cancer Res 38: 1723–1729

    PubMed  Google Scholar 

  73. Leclerc JM, Cheng YC (1984) Demonstration of activities in leukemic cells capable of removing 1-β-D-arabinofuranosyl-cytosine (ara-C) from ara-C incorporated DNA. Proc Am Assoc Cancer Res 25: 19

    Google Scholar 

  74. Liliemark JO, Plunkett W, Dixon DO (1985) Relationship of 1-β-D-arabinofuranosylcytosine in plasma to 1-β-D-arabino-furanosylcytosine 5′triphosphate levels in leukemic cells during treatment with high-dose 1-β-D-arabinofuranosylcytosine. Cancer Res 45: 5952–5957

    PubMed  Google Scholar 

  75. Major P, Egan EM, Beardsley GP, Minden MD, Kufe DW (1981) Lethality of human myeloblasts correlates with the incorporation of Ara-C into DNA. Proc Natl Acad Sci USA 78: 3235–3239

    PubMed  Google Scholar 

  76. Mayer RJ, Schiffer CA, Peterson BA, Budman DR, Silver RT, Rai KR, Cornwall GG, Ellison RR, Maguire M, Berg DT, Davis RB, McIntyre OR, Frei E III (1987) Intensive postremission therapy in adults with acute nonlymphocytic leukemia using various schedules of ara-C: a progress report from CALGB. Semin Oncol 14 [Suppl 1]: 25–31

    PubMed  Google Scholar 

  77. Momparler RL, Chu MY, Fischer GA (1968) Studies on a new mechanism of resistance of L 5178 murine leukemia cells to cytosine arabinoside. Biochem Biophys Acta 161: 481–493

    PubMed  Google Scholar 

  78. Momparler RL, Fischer GA (1968) Mammalian deoxynucleoside kinase. I. Deoxycytidine kinase: purification, properties, and kinetic studies with cytosine arabinoside. J Biol Chem 243: 4298–4304

    PubMed  Google Scholar 

  79. Momparler RL (1969) Effect of cytosine arabinoside triphosphate on mammalian DNA polymerase. Biochem Biophys Res Commun 43: 465–471

    Google Scholar 

  80. Momparler RL (1972) Kinetic and template studies with 1-β-D-arabinofuranosylcytosine 5′triphosphate and mammalian deoxyribonucleic acid polymerase. Mol Pharmacol 8: 362–370

    PubMed  Google Scholar 

  81. Momparler RL (1974) A model for the chemotherapy of acute leukemia with 1-β-D-arabinofuranosylcytosine. Cancer Res 34: 1775–1787

    PubMed  Google Scholar 

  82. Muhm M, Andreeff M, Geissler K, Gorischek C, Haas O, Haimi J, Hinterberger W, Schulz G, Speiser W, Sunder-Plassmann G, Valent P, Lechner K, Bettelheim P (1989) RhGM-CSF in combination with chemotherapy — a new strategy in the therapy of acute myeloid leukemia. Blood 74 [Suppl 1]: 117a

    Google Scholar 

  83. Muus P, van den Bogert C, Haanen C, Pennings A, Melis TE (1991) 1-β-D-arabinofuranosylcytosine enhances mitochondrial activities in human leukemic cells. Cancer Res (in press)

  84. Peters WG, Willemze R, Colly LP (1987) Intermediate and high-dose cytosine arabinoside-containing regimens for induction and consolidation therapy for patients with acute lymphoblastic leukemia and lymphoblastic non-Hodgkin's lymphoma: the Leyden experience and review of the literature. Semin Oncol 14 [Suppl 1]: 86–91

    PubMed  Google Scholar 

  85. Peters WG, Colly LP, Willemze R (1988) High-dose cytosine arabinoside: pharmacological and clinical aspects. Blut 56: 1–11

    PubMed  Google Scholar 

  86. Plunkett W, Jacoboni S, Estey E, Danhauser L, Liliemark JO, Keating MJ (1985) Pharmacologically directed ara-C therapy for refractory leukemia. Semin Oncol 12 [Suppl 3]: 20–30

    Google Scholar 

  87. Plunkett W, Liliemark JO, Adams TM, Nowak D-B, Estey E, Kantarjian H, Keating MJ (1987) Saturation of 1-beta-arabinofuranosylcytosine 5′-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy. Cancer Res 47: 3005–3011

    PubMed  Google Scholar 

  88. Plunkett W, Heinemann V, Estey E, Keating MJ (1990) Pharmacologically directed design of leukemia therapy. In: Büchner T, Schellong G, Hiddemann W, Ritter J (eds) Acute leukemias — prognostic factors and treatment strategies II. Springer, Berlin Heidelberg New York, pp 610–613

    Google Scholar 

  89. Powell BL, Capizzi RL, Muss HB, Bearden JD, Lyerly ES, Rosenbaum DL et al. (1989) Low-dose Ara-C therapy for acute myelogenous leukemia in elderly patients. Leukemia 3: 23–28

    PubMed  Google Scholar 

  90. Preisler HD, Epstein J, Barcos M, Priore R, Raza A, Browman GP, Vogler R, Winton E, Grunwald H, Rai K, Brennan J, Bennett J, Goldberg J, Gottlieb A, Chervenick P, Joyce R, Miller K, Larson R, D'Arrigo P, Doeblin T, Stein M, Bloom M, Steele R, Lee H (1984) Prediction of response of acute nonlymphocytic leukaemia to therapy with “high-dose” cytosine arabinoside. Br J Haematol 58: 19–32

    PubMed  Google Scholar 

  91. Preisler HR, Raza A, Barcos M, Azarnia N, Larson R, Walker I, Browman M, Grunwald H, D'Arrigo P, Doeblin T, Bloom M, Stein A, Logue G, Goldberg J, Kirshner J, Gottlieb A, Bennett J (1987) High-dose cytosine arabinoside as the initial treatment of poor-risk patients with acute nonlymphocytic leukemia: a leukemia intergroup study. J Clin Oncol 5: 75–82

    PubMed  Google Scholar 

  92. Raza A, Maheshwari Y, Mandava N, Yasin Z, Perveen S, Mayers G, Browman G, Goldberg J, Gottlieb A, Grunwald H, Larson R, Miller K, Vogler R, Preisler HD (1987) Cell cycle and drug sensitivity studies of leukemic cells that appear relevant in determining response to chemotherapy in acute nonlymphocytic leukemia. Semin Oncol 14 [Suppl 1]: 217–225

    PubMed  Google Scholar 

  93. Riva CM, Rustum YM, Preisler HD (1985) Pharmacokinetics and cellular determinants of response to 1-beta-arabinofuranosylcytosine (ARAC). Semin Oncol 12 [Suppl 3]: 1–8

    Google Scholar 

  94. Rohatiner A, Slevin ML, Dhaliwal HS, Malpas JS, Lister TA (1984) High-dose cytosine arabinoside: response to therapy in acute leukaemia and non-Hodgkin's lymphoma. Cancer Chemother Pharmacol 12: 90–93

    PubMed  Google Scholar 

  95. Ross DD, Thompson BWQ, Joneckis CC, Akman SA, Schiffer CA (1986) Metabolism of ara-C by blast cells from patients with ANLL. Blood 68: 76–82

    PubMed  Google Scholar 

  96. Rudnick SA, Cadman EC, Capizzi RL, Skeel RT, Bertino JR, McIntosh S (1979) High-dose cytosine arabinoside in refractory acute leukemia. Cancer 44: 1189–1193

    PubMed  Google Scholar 

  97. Rustum Y, Preisler HD (1979) Correlation between leukemic cell retention of 1-β-D-arabinofuranosylcytosine 5′-triphosphate and response to therapy. Cancer Res 39: 42–47

    PubMed  Google Scholar 

  98. Rustum YM, Slocum HK, Wang G, Bakshi D, Kelly E, Buscagalia D, Wrzosek C, Early AP, Preisler H (1982) Relationship between plasma Ara-C and intercellular ARA-CTP pools under conditions of continuous infusion and high-dose ARAC treatment. Med Pediatr Oncol 1: 33–43

    Google Scholar 

  99. Rustum YM, Riva C, Preisler HD (1987) Pharmacokinetic parameters of 1-β-D-arabinofuranosylcytosine (ara-C) and their relationship to intracellular metabolism of ara-C, toxicity, and response of patients with conventional and high-dose ara-C. Semin Oncol 14 [Suppl 1]: 141–148

    PubMed  Google Scholar 

  100. Schiller GJ, Ho WG, Gajewski JL, Nimer SD, Champlin RE (1990) Randomized controlled study of intermediate- vs. standard-dose cytarabine and daunorubicin for induction treatment of acute myelogenous leukemia. Proc Am Soc Clin Oncol 9: 204

    Google Scholar 

  101. Slevin ML, Piall EM, Aherne GM, Harvey VJ, Johnston A, Lister TA (1983) Effect of dose and schedule on pharmaco-kinetics of cytosine arabinoside in plasma and cerebrospinal fluid. J Clin Oncol 1: 546–551

    PubMed  Google Scholar 

  102. Spriggs D, Robbins G, Ohno Y, Kute D (1987) Detection of 1-β-D-arabinofuranosyl cytosine incorporation into DNA in vivo. Cancer Res 47: 6532–6536

    PubMed  Google Scholar 

  103. Steuart CD, Burke PJ (1971) Cytidine deaminase and the development of resistance to arabinosylcytosine. Nature New Biol 233: 109–110

    PubMed  Google Scholar 

  104. Tafuri A, Lemoll M, Gulati S, Clarkson B, Andreeff M (1989) Rationale and limitations of combined cytokine chemotherapy treatment of acute myeloblastic leukemia (AML). Blood 74 [Suppl 1]: 231a

    Google Scholar 

  105. Takaku F, Urabe A, Mizoguchi H, Yamada O, Wakabayashi Y, Miura Y, Sakamoto S, Yoshida M, Miwa S, Asano S, Morsaki T, Nomura T, Toyama K, Aoki I, Murase T, Maekawa T, Miyawaki S, Murakami H, Yamada H, Ohno R, Kawashima K, Yokomaku S, Kinugasa K, Adachi Y, Mori M, Ise T, Mutoh Y, Yamaguchi H (1985) High-dose cytosine arabinoside in the treatment of resistant acute leukemia. Semin Oncol 12 [Suppl 3]: 144–149

    PubMed  Google Scholar 

  106. Talley RW, Vaitkevicius VK (1963) Megaloblastosis produced by cytosine antagonist 1-β-D-arabinofuranosylcytosine. Blood 21: 352–362

    PubMed  Google Scholar 

  107. Tallman MS, Appelbaum FR, Amos D, Goldberg RS, Livingston RB, Mortimer J, Weiden PL, Thomas ED (1967) Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide. J Clin Oncol 5: 918–926

    Google Scholar 

  108. Tanaka M, Yoshida S (1982) Altered sensitivity to 1-β-D-arabinofuranosylcytosine 5′-triphosphate of DNA polymerase from leukemic blasts of acute lymphoblastic leukemia. Cancer Res 42: 649–653

    PubMed  Google Scholar 

  109. Uhrmeister Ch, Schleyer E, Ehninger G, Büchner T, Hiddemann W (1989) Pharmacokinetic measurements of Ara-C, Ara-U and intercellular Ara-CTP under sequential HAM therapy. Blut 59: 127

    Google Scholar 

  110. van Prooijen HC (1977) Pharmacokinetics of cytosine arabinoside in acute myeloid leukaemia. Thesis, Krips Repro-Meppel

  111. van Prooijen HC, Dekker AW, Punt K (1984) The use of intermediate-dose cytosine arabinoside (ID-AraC) in the treatment of acute non-lymphocytic leukaemia in relapse. Br J Haematol 57: 291–299

    PubMed  Google Scholar 

  112. Vaughan WP, Karp JE, Burke PJ (1984) Two-cycle timed sequential chemotherapy for adult acute nonlymphocytic leukemia. Blood 64: 975–980

    PubMed  Google Scholar 

  113. Vogler WR, Preisler HD, Winton EF, Gottlieb AJ, Goldberg J, Brennan J, Grunwald H, Rai K, Browman G, Miller KB, Chervenick P, Azarnia N (1986) Randomized trial of highdose cytarabine versus amsacrine in acute myelogenous leukemia in relapse: a Leukemia Intergroup study. Cancer Treat Rep 10: 455–459

    Google Scholar 

  114. Wan SH, Hoffmann DH, Azarnoff DL (1974) Pharmacokinetics of 1-β-D-furanosylcytosine in humans. Cancer Res 34: 392–397

    PubMed  Google Scholar 

  115. Wan CW, Mak TW (1978) Deoxycytidine kinase and cytosine nucleoside deaminase activities in synchronized cultures of normal rat kidney cells. Cancer Res 38: 2768–2772

    PubMed  Google Scholar 

  116. Weinstein HJ, Griffin TW, Feeney J, Cohen HJ, Propper RD, Sallan SE (1982) Pharmacokinetics of continuous intravenous and subcutaneous infusions of cytosine arabinoside. Blood 59: 1351–1353

    PubMed  Google Scholar 

  117. White JC, Rathmell JP, Capizzi RL (1987) Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemia cells. J Clin Invest 79: 380–387

    PubMed  Google Scholar 

  118. Wiley JS, Jones SP, Sawyer WH, Paterson ARP (1982) Cytosine arabinoside influx and nucleoside transport sites in acute leukemia. J Clin Invest 69: 479–489

    PubMed  Google Scholar 

  119. Willemze R, Zwaan FE, Colpin G, Keuning JJ (1982) Highdose cytosine arabinoside in the management of refractory acute leukemia. Scand J Haematol 29: 141–146

    PubMed  Google Scholar 

  120. Willemze R, Fibbe WE, Zwaan FE (1983) Experience with intermediate and high-dose cytosine arabinoside in refractory acute leukemia. Onkologie 6: 200–204

    PubMed  Google Scholar 

  121. Wodinsky I, Kensler CJ (1965) Activity of cytosine arabinoside (NSC 63838) in a spectrum of rodent tumors. Cancer Chemother Rep 47: 65–69

    PubMed  Google Scholar 

  122. Wolff SN, Herzig RH, Fay JW, Phillips GL, Lazarus HM, Flexner JM, Stein RS, Greer JP, Cooper B, Herzig GP (1989) High-dose cytarabine and daunorubicin as consolidation for acute myeloid leukemia in first remission: long-term follow-up and results. J Clin Oncol 7: 1260–1267

    PubMed  Google Scholar 

  123. Zittoun R, Zittoun J, Rustum Y, Creaven P (1985) Modulation of 1-β-D-arabinofuranosylcytosine metabolism by thymidine in human acute leukemia. Cancer Res 45: 5186–5192

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, University of Münster, Albert-Schweitzer-Strasse 33, W-4400, Münster, Federal Republic of Germany

    W. Hiddemann

Authors
  1. W. Hiddemann
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hiddemann, W. Cytosine arabinoside in the treatment of acute myeloid leukemia: The role and place of high-dose regimens. Ann Hematol 62, 119–128 (1991). https://doi.org/10.1007/BF01702925

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01702925

Key words

Search

Navigation